Free Trial

Acurx Pharmaceuticals (ACXP) Competitors

Acurx Pharmaceuticals logo
$0.89 +0.05 (+5.94%)
As of 01/3/2025 05:38 PM Eastern

ACXP vs. KRON, GANX, SPRO, VIRI, MURA, DYAI, RPTX, ALVR, ITRM, and ALRN

Should you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Kronos Bio (KRON), Gain Therapeutics (GANX), Spero Therapeutics (SPRO), Virios Therapeutics (VIRI), Mural Oncology (MURA), Dyadic International (DYAI), Repare Therapeutics (RPTX), AlloVir (ALVR), Iterum Therapeutics (ITRM), and Aileron Therapeutics (ALRN). These companies are all part of the "pharmaceutical products" industry.

Acurx Pharmaceuticals vs.

Acurx Pharmaceuticals (NASDAQ:ACXP) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Acurx Pharmaceuticals has a beta of -1.86, indicating that its stock price is 286% less volatile than the S&P 500. Comparatively, Kronos Bio has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500.

Kronos Bio received 7 more outperform votes than Acurx Pharmaceuticals when rated by MarketBeat users. However, 93.33% of users gave Acurx Pharmaceuticals an outperform vote while only 65.63% of users gave Kronos Bio an outperform vote.

CompanyUnderperformOutperform
Acurx PharmaceuticalsOutperform Votes
14
93.33%
Underperform Votes
1
6.67%
Kronos BioOutperform Votes
21
65.63%
Underperform Votes
11
34.38%

11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 64.1% of Kronos Bio shares are held by institutional investors. 29.6% of Acurx Pharmaceuticals shares are held by insiders. Comparatively, 24.4% of Kronos Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Acurx Pharmaceuticals has a net margin of 0.00% compared to Kronos Bio's net margin of -867.66%. Kronos Bio's return on equity of -64.55% beat Acurx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Acurx PharmaceuticalsN/A -392.36% -223.78%
Kronos Bio -867.66%-64.55%-48.18%

Acurx Pharmaceuticals currently has a consensus price target of $12.00, suggesting a potential upside of 1,248.47%. Kronos Bio has a consensus price target of $1.63, suggesting a potential upside of 62.50%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Acurx Pharmaceuticals is more favorable than Kronos Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acurx Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Kronos Bio
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Acurx Pharmaceuticals had 5 more articles in the media than Kronos Bio. MarketBeat recorded 6 mentions for Acurx Pharmaceuticals and 1 mentions for Kronos Bio. Acurx Pharmaceuticals' average media sentiment score of 1.73 beat Kronos Bio's score of 0.78 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Acurx Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Kronos Bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Acurx Pharmaceuticals has higher earnings, but lower revenue than Kronos Bio. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Kronos Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acurx PharmaceuticalsN/AN/A-$14.58M-$1.09-0.82
Kronos Bio$9.86M6.12-$112.67M-$1.43-0.70

Summary

Acurx Pharmaceuticals beats Kronos Bio on 9 of the 16 factors compared between the two stocks.

Get Acurx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACXP vs. The Competition

MetricAcurx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$15.03M$6.62B$5.21B$9.05B
Dividend YieldN/A2.92%4.99%4.15%
P/E Ratio-0.8210.7887.7617.30
Price / SalesN/A161.941,150.09121.20
Price / CashN/A57.1143.2637.87
Price / Book2.625.255.185.18
Net Income-$14.58M$153.25M$121.62M$226.86M
7 Day Performance-0.46%4.84%3.64%3.12%
1 Month Performance15.72%0.52%21.12%4.42%
1 Year Performance-77.53%5.93%30.61%21.89%

Acurx Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACXP
Acurx Pharmaceuticals
2.6358 of 5 stars
$0.89
+5.9%
$12.00
+1,248.5%
-78.4%$15.03MN/A-0.823Short Interest ↑
Positive News
KRON
Kronos Bio
2.9068 of 5 stars
$0.93
-0.7%
$1.63
+74.2%
-10.7%$56.30M$9.86M-0.65100Positive News
Gap Down
GANX
Gain Therapeutics
3.5324 of 5 stars
$2.06
+17.0%
$7.25
+251.9%
-31.2%$54.64M$50,000.00-1.8720Gap Up
SPRO
Spero Therapeutics
4.6045 of 5 stars
$1.00
-2.9%
$5.00
+400.1%
-25.2%$54.51M$89.87M14.2946
VIRI
Virios Therapeutics
0.4867 of 5 stars
$2.82
+7.6%
$3.00
+6.4%
+370.1%$54.31MN/A-10.445News Coverage
Gap Up
MURA
Mural Oncology
3.453 of 5 stars
$3.16
-1.9%
$16.00
+406.3%
-37.9%$53.78MN/A-0.35119
DYAI
Dyadic International
2.6937 of 5 stars
$1.82
-7.4%
$6.00
+230.6%
+15.0%$53.70M$3.36M-7.897News Coverage
High Trading Volume
RPTX
Repare Therapeutics
2.7614 of 5 stars
$1.23
-4.7%
$7.00
+469.1%
-80.2%$52.29M$66.52M-0.62180High Trading Volume
ALVR
AlloVir
2.9905 of 5 stars
$0.45
-2.6%
N/A-29.0%$51.44MN/A-0.51110Positive News
Gap Down
ITRM
Iterum Therapeutics
2.6594 of 5 stars
$1.84
-3.2%
$5.00
+171.7%
-3.6%$50.63MN/A-0.9210
ALRN
Aileron Therapeutics
4.0988 of 5 stars
$2.30
+3.1%
$19.00
+726.1%
-31.3%$49.83MN/A-0.749Positive News

Related Companies and Tools


This page (NASDAQ:ACXP) was last updated on 1/4/2025 by MarketBeat.com Staff
From Our Partners